Phase II Study of Faslodex ® in Recurrent/Metastatic Endometrial Carcinoma

Trial Profile

Phase II Study of Faslodex ® in Recurrent/Metastatic Endometrial Carcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2010 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University record no. GOG0188).
    • 26 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Apr 2009 Status changed from suspended to recruiting as reported by M.D. Anderson Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top